These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30293724)

  • 21. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk.
    Lambert JC; Araria-Goumidi L; Myllykangas L; Ellis C; Wang JC; Bullido MJ; Harris JM; Artiga MJ; Hernandez D; Kwon JM; Frigard B; Petersen RC; Cumming AM; Pasquier F; Sastre I; Tienari PJ; Frank A; Sulkava R; Morris JC; St Clair D; Mann DM; Wavrant-DeVrièze F; Ezquerra-Trabalon M; Amouyel P; Hardy J; Haltia M; Valdivieso F; Goate AM; Pérez-Tur J; Lendon CL; Chartier-Harlin MC
    Neurology; 2002 Jul; 59(1):59-66. PubMed ID: 12105308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-ɛ4 allele carriers aged 45-75: Results from the ALFA study.
    Rojas S; Brugulat-Serrat A; Bargalló N; Minguillón C; Tucholka A; Falcon C; Carvalho A; Morán S; Esteller M; Gramunt N; Fauria K; Camí J; Molinuevo JL; Gispert JD
    J Cereb Blood Flow Metab; 2018 Feb; 38(2):250-261. PubMed ID: 28492093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein E genotypes in hospitalized elderly patients with vascular dementia.
    Orsitto G; Seripa D; Panza F; Franceschi M; Cascavilla L; Placentino G; Matera MG; Paris F; Capurso C; Solfrizzi V; Dallapiccola B; Pilotto A
    Dement Geriatr Cogn Disord; 2007; 23(5):327-33. PubMed ID: 17374951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of an APOE promoter polymorphism on human cortical morphology during nondemented aging.
    Chen Y; Li P; Gu B; Liu Z; Li X; Evans AC; Gong G; Zhang Z
    J Neurosci; 2015 Jan; 35(4):1423-31. PubMed ID: 25632120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of an APOE Promoter Polymorphism on Human White Matter Connectivity during Non-Demented Aging.
    Chang P; Li X; Ma C; Zhang S; Liu Z; Chen K; Ai L; Chang J; Zhang Z
    J Alzheimers Dis; 2017; 55(1):77-87. PubMed ID: 27636845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart diseases and long-term risk of dementia and Alzheimer's disease: a population-based CAIDE study.
    Rusanen M; Kivipelto M; Levälahti E; Laatikainen T; Tuomilehto J; Soininen H; Ngandu T
    J Alzheimers Dis; 2014; 42(1):183-91. PubMed ID: 24825565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apolipoprotein E epsilon 4 genotype and a physically active lifestyle in late life: analysis of gene-environment interaction for the risk of dementia and Alzheimer's disease dementia.
    Luck T; Riedel-Heller SG; Luppa M; Wiese B; Köhler M; Jessen F; Bickel H; Weyerer S; Pentzek M; König HH; Prokein J; Ernst A; Wagner M; Mösch E; Werle J; Fuchs A; Brettschneider C; Scherer M; Maier W
    Psychol Med; 2014 Apr; 44(6):1319-29. PubMed ID: 23883793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E epsilon4, Alzheimer's disease, and cognitive performance in elderly Mexican Mestizos.
    Villalpando-Berumen JM; Mejia-Arango S; Aguilar-Salinas CA; Ordonez-Sanchez ML; Gutierrez-Robledo LM
    J Am Geriatr Soc; 2008 Apr; 56(4):677-82. PubMed ID: 18205760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers.
    Xu WL; Caracciolo B; Wang HX; Santoni G; Winblad B; Fratiglioni L
    J Alzheimers Dis; 2013; 33(2):507-15. PubMed ID: 23247007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.
    Huang W; Qiu C; von Strauss E; Winblad B; Fratiglioni L
    Arch Neurol; 2004 Dec; 61(12):1930-4. PubMed ID: 15596614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].
    Rosich-Estragó M; Figuera-Terré L; Mulet-Pérez B; Arrufat-Cardús MT; Pascual San Emeterio A; Arbeola-Rigau I; Labad-Alquézar A; Vilella-Cuadrada E
    Rev Neurol; 2004 May 1-15; 38(9):801-7. PubMed ID: 15152345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population-based study.
    Pink A; Stokin GB; Bartley MM; Roberts RO; Sochor O; Machulda MM; Krell-Roesch J; Knopman DS; Acosta JI; Christianson TJ; Pankratz VS; Mielke MM; Petersen RC; Geda YE
    Neurology; 2015 Mar; 84(9):935-43. PubMed ID: 25653291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.
    Bullido MJ; Artiga MJ; Recuero M; Sastre I; García MA; Aldudo J; Lendon C; Han SW; Morris JC; Frank A; Vázquez J; Goate A; Valdivieso F
    Nat Genet; 1998 Jan; 18(1):69-71. PubMed ID: 9425904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of MAPT H1 and APOE ε4 on transition from mild cognitive impairment to dementia.
    Samaranch L; Cervantes S; Barabash A; Alonso A; Cabranes JA; Lamet I; Ancín I; Lorenzo E; Martínez-Lage P; Marcos A; Clarimón J; Alcolea D; Lleó A; Blesa R; Gómez-Isla T; Pastor P
    J Alzheimers Dis; 2010; 22(4):1065-71. PubMed ID: 20930301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer's Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort.
    Chai YL; Yeo HK; Wang J; Hilal S; Ikram MK; Venketasubramanian N; Wong BS; Chen CL
    J Alzheimers Dis; 2016; 51(4):1111-8. PubMed ID: 26923016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.
    Yip AG; Brayne C; Easton D; Rubinsztein DC;
    J Med Genet; 2002 Sep; 39(9):639-43. PubMed ID: 12205106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.
    Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW
    Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele.
    Rajan KB; Barnes LL; Wilson RS; Weuve J; McAninch EA; Evans DA
    Ann Neurol; 2018 May; 83(5):935-944. PubMed ID: 29637601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein E genotype and cerebrovascular alterations can influence conversion to dementia in patients with mild cognitive impairment.
    Viticchi G; Falsetti L; Vernieri F; Altamura C; Altavilla R; Luzzi S; Bartolini M; Provinciali L; Silvestrini M
    J Alzheimers Dis; 2014; 41(2):401-10. PubMed ID: 24625799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4.
    Huang TL; Zandi PP; Tucker KL; Fitzpatrick AL; Kuller LH; Fried LP; Burke GL; Carlson MC
    Neurology; 2005 Nov; 65(9):1409-14. PubMed ID: 16275829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.